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The possible role of cyclic AMP (CAMP) in the regulation of the vasopressin (VP) gene was tested in two cellular expression systems: one cell 
line with endogenous VP expression and the other which was transiently with a VP promoter-luciferase fusion gene. 8,Bromo-CAMP stimulated 
the VP mRNA content about 4-fold in the human VP-expressing small cell lung carcinoma cell line GLC-8. The luciferase activity in P19 embryonal 
carcinoma cells which were transiently transfected with - 174 to +44 of the 5’-flanking region of the human VP gene linked to the firefly luciferase 
gene, was stimulated about 2-fold by the CAMP analogue. The results indicate that CAMP plays a role in the upregulation of the VP gene and 
hence point to several putative nucleotide motives in the promoter functionally conferring this response. 
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1. INTRODUCTION 
The hormonal control of fluid homeostasis involves 
vasopressin (VP) which originates from magnocellular 
neurons in the hypothalamus. These neurons are 
clustered in the supraoptic (SON) and paraventricular 
(PVN) nuclei and express the VP gene [1,2]. VP gene 
products are transported to the neural lobe of the 
pituitary gland, where they are secreted into the circula- 
tion [3]. 
In the SON and the PVN, VP gene expression is 
critically altered by changes in osmotic balance as 
shown by the increase in VP mRNA content in salt 
loaded or dehydrated rats [4-61. Furthermore, changes 
in VP gene expression have been found during develop- 
ment, gestation and lactation [7-g]. Electrophysio- 
logical and morpholocial studies have indicated that the 
activity of VP neurons is controlled by neuronal inputs 
[lo, 111, thus pointing to an involvement of second 
messengers in mediating effects of transmitters on gene 
expression. Three lines of experiments suggest that 
CAMP may be one of the involved second messengers. 
Firstly, hyperosmolality caused an increase in the levels 
of CAMP [12] and of the G protein a-subunit mRNA 
[13]. Secondly, CAMP increased the number of VP 
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mRNA containing neurons in a primary culture [ 141, 
and thirdly, the 5 ’ flanking regions of human and rat 
genes contain nucleotide sequences which resemble 
AP-2 binding elements [1% 171. To directly investigate 
the influence of CAMP on VP mRNA synthesis, we here 
use the human small cell lung carcinoma (SCLC) cell 
line GLC-8 with endogenous expression of the VP gene 
(Verbeeck et al., unpublished data). Here we report the 
effect of CAMP on VP mRNA levels in this cell line and 
on VP promoter activity with a promoter-luciferase fu- 
sion gene in a heterologous expression system. 
2. MATERIALS AND METHODS 
2.1. Genomic analysis 
GLC-8 cells (5 x 10’) were washed in phosphate-buffered saline (pH 
7.4) and DNA was prepared from isolated nuclei [18]. 15 pg was 
digested with restriction enzymes EcoRI, BarnHI or HindIII, loaded 
on 0.7% agarose gel and run at 1 V/cm. The gel was then blotted on 
a nylon filter (Zeta probe, Bio-Rad, Richman, CA) in 2 M sodium 
hydroxide for 5 h. The Southern blot was prehybridized at 70°C in 
1.5 x SSPE (0.18 M sodium chloride, 10 mM sodium phosphate (pH 
7.0) and 1 mM EDTA), 2% SDS, 1% defatted milk powder (Refit, 
Campina, Eindhoven, The Netherlands) and 1 mg/ml denatured her- 
ring sperm DNA for 5 h. Hybridization was performed simultaneous- 
ly with two ‘*P-labelled genomic probes (3 x lo6 cpm/ml) in 
1.5 x SSPE, 1% SDS, 0.5% milk powder, 10% dextran sulphate and 
0.5 mg/ml denatured herring sperm DNA at 70°C for 16 h. One probe 
was the BumHI-P&I fragment of the human VP gene containing 169 
bp of the first exon, and the other was the HgiAI-BumHI genomic 
fragment containing 255 bp of the last exon of the VP gene [19]. Blots 
were washed successively in 2 x SSC (1 x SSC = 0.15 M NaCl, 0.015 M 
sodium citrate, pH 7.0), 0.1% SDS at room temperature for 20 min, 
in 0.5 x SSC at 50°C for 30 min and in 0.1 x SSC at 50°C for 10 min. 
Blots were exposed to X-ray film (Kodak, X-OMAT) with an intensi- 
fying screen at - 80°C for 20 h. 
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2.2. RNA rsolation and analysis 
Total cellular RNA of (2.5-5) x 10’ cells was prepared as described 
by Wilkinson [20]. Cells ((2.5-5) x 10’) were resuspended in 400~1 ice- 
cold Tris-saline (25 mM Tris (pH 7.4), 130 mM NaCl, 5 mM KCI). 100 
pl ice-cold NND buffer (1% Nonidet P-40, 0.5% sodium deox- 
ycholate and 0.01% dextran sulphate made up in Tris-saline) was 
gently mixed. The homogenate was spun in an Eppendorf centrifuge 
at 4°C for 30 s. The pellet was stored and used later for the determina- 
tion of the DNA content [21]. The supernatant was extracted twice 
with an equal volume of phenol/chloroform/isoamylalchol 
(25 :24: 1). RNA was precipitated overnight at - 20°C after sup- 
plementing 1 ml 100070 ethanol. After precipitation the pellets were 
dissolved in 20 mM Tris (pH 7.4), 1 mM EDTA and the amount of 
RNA was determined spectrophotometrically by UV absorption at 
260 nm. 
For Northern blotting total RNA (2Opg) was denatured with glyox- 
al and dimethylsulphoxide in 10 mM phosphate buffer (pH 6.5) at 
55°C for 60 min, cooled on ice, loaded on a 1.4% agarose-10 mM 
phosphate gel and run at 10 V/cm for 3 h. Transfer of RNA from the 
gel to a nylon membrane (Hybond-N, Amersham, UK) was carried 
out overnight in 25 mM phosphate buffer (pH 6.5). The blot was 
briefly washed in 2xSSC and baked at 80°C for 2 h. Filters were 
prehybridized in 50% (v/v) formamide, 6x SSC, 8% dextran 
sulphate, 0.5 mg/ml denatured herring sperm DNA and 0.5% (w/v) 
defatted milk powder at 50°C for at least 6 h. Denatured 3ZP-labelled 
DNA probes were added to the prehybridization mix to a final con- 
centration of at least 2x lo6 cpm/ml at 50°C and incubated over- 
night. The VP-specific probe was the HgiAI-EamHI genomic frag- 
ment containing 225 bp of the last exon of VP [19]. The blots were 
also separately hybridized with the rat P-actin specific probe, which 
was the PstI fragment (about 1500 bp) of the rat cDNA clone [22]. 
The filters were washed twice in 2 x SSC, 0.1% SDS at room 
temperature for 5 min, followed by one wash at 50°C for 30 min, one 
wash at 60°C for 20 min and a final wash in 0.1 x SSC, 0.1% SDS and 
1 mM EDTA at 65°C for 20 min. The filters were then exposed to 
X-ray film (Kodak X-OMAT) with an intensifying screen at - 80°C 
for various lengths of time. The optical density of the lanes on the 
films was determined with an one-dimensional densitometric scanner 
(Zeiss KM3, Oberkochen, FRG). 
2.3. Treatment and transfectron of cell lines 
SCLC GLC-8 cells [23] were cultured in RPM1 medium (Gibco 
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Fig. 1. Analysis of the VP locus in the cell line SCLC GLC-8. (A) Genomic map of the VP gene locus. In the upper part of the figure exons A, 
B and C are represented by w. The position of the oxpocin gene and several restriction sites have been taken from Sausville et al. [19]. Other sites 
were determined by Southern analysis (see panel B). (B) Genomic fragments containing VP sequences of human placenta and SCLC cells. Samples 
of genomic DNA (15 yg) of GLC-8 passage 27 (a), GLC-8 passage 91 (b) and human placenta (c) were digested with BarnHI, Hind111 or EcoRI, 
electrophoresed and transferred to a nylon membrane. The Southern blot was hybridized with two probes simultaneously: one probe of 345 bp 
containing a part of exon A of VP, the other of 525 bp containing a part of exon C of VP. The exposure time was 24 h. For details see Materials 
and Methods. 
90 
Volume 272, number 1,2 FEBSLETTERS October 1990 
Europe, Breda, The Netherl~ds~, supplements with 10% calf serum 
(High Clone, Greiner Laboratories, Life Technologies Inc., Grand 
Island, New York, USA), 2 mM glutamine (Gibco), 100 units/ml 
penicillin-streptomycin (Gibco), 0.5 mM ,&mercaptoethanol (Merck, 
Darmstadt, FRG), 1 mM sodiumpyruvate (Sigma Chemical Co., St. 
Louis, USA), 2.5 pg/ml fungizon (Cibco) and 60 &ml gentamycin 
(Gibco). Before incubation with 0.5 mM, 8,Bromo-CAMP 
(B~h~nger-M~nheim, FRG) and 0.5 mM isobutyl-methy~anthine 
(IMBX) ~oeh~nger-Mannheim), the cells were kept on stripped, 
steroid-free serum for 24 h. The vehicle for 8,Br-CAMP and IBMX 
was ethanol. After 8,Br-CAMP and IBMX treatment for 50 h samples 
of about 5 x lo7 cells were harvested. 
P19 embryonal carcinoma (EC) cells 1241 were cultured in DMEM 
(Gibco) supplemented with 7.5% fetal calf serum. The 5’-flanking 
region of the human VP gene, from position - 174 to +44 [19], was 
fused to the luciferase gene in pl9LUC 1251 to create pHVPLUC. 10 
Fug of pHVPLUC was transfected with the calcium-phosphate 
precipitation method as described [26]. One day after transfection the 
medium was replaced and the cells received fresh medium containing 
0.5 mM 8,Br-CAMP and/or 0.5 mM IBMX. After 24 h the cells were 
harvested in 35OpllOO mM potassium phosphate (pH 7.8) with 1 r&l 
dit~othreitol (~hringer-M~nheim) and iuciferase was measured in 
60 /cl of extract according to the protocol of de Wet 1271, using a 
Lumacl3m biocounter M2010A luminometer. 
3. RESULTS AND DISCUSSION 
The SCLC cell line GLC-8 has been identified before 
among three VP-expressing SCLC cell lines as the one 
with the highest levels of VP mRNA (Verbeeck et al., 
unpublished data). Before use in studies on the regula- 
tion of the VP gene, the VP locus in this cell line was 
analyzed on genomic blots. The three restriction en- 
zymes used produced the same restriction fragments of 
GLC-8 DNA from two passages as normal placenta 
DNA (Fig. 1A). The intensity of the signals was ap- 
proximately the same. This result indicates that there 
are no serious rearrangements or amplifications of the 
VP gene locus over about 15 kb 5 ’ upstream to 20 kb 
downstream of the VP gene in this cell line (Fig. 1B). 
Thus, SCLC GLC-8 was then used to study the role of 
CAMP in the regulation of endogenous VP mRNA 
levels. 
Treatment of SCLC GLC-8 cells with 0.5 mM of the 
CAMP analogue 8,Br-CAMP in the presence of 0.5 mM 
IBMX and ethanol as vehicles caused a marked increase 
in the VP mRNA level as compared to cells which were 
cultured under identical conditions without 8,Br-CAMP 
(Fig. 2A). IBMX or ethanol alone had no significant ef- 
fect on the VP mRNA level as compared to untreated 
cells, but the compounds together caused a reduction of 
the VP mRNA content. On the basis of the @-a&in 
mRNA content, 8,Br-CAMP stimulated the VP mRNA 
content approximately 4-fold (average of three ex- 
periments; Fig. 2B). There was no significant effect of 
8,Br-CAMP on the&action mRNA and total RNA con- 
tents per cell, nor an effect on the total cell number. The 
results thus show that the steady-state level of VP 
mRNA is increased by the CAMP analogue. 
To investigate whether transcriptional regulation was 
involved in the increase in VP mRNA level, the effect of 
the CAMP analogue on the activity of the VP promoter 
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Fig. 2. Effect of 8,Br-CAMP treatment on VP mRNA levels in SCLC 
GLC-8 ceils. (A) Northern blot with 20 pg total RNA of SCLC 
GLC-8. Lanes 1 and 3 represent two GLC-8 cultures separately 
treated with 0.5 mM IBMX alone, lanes 2 and 4 represent two GLC-8 
cell cultures separately treated with 0.5 mM IBMX and 0.5 mM 8,Br- 
CAMP. Both treatments lasted for 50 h. The filter was hybridized with 
random primer labelled VP-specific probe containing VP exon C [19] 
and later with a@-actin-specific probe [22]. The exposure time was 24 
h. For details see Materials and Methods. (*marks the 28 S ribosomal 
RNA; ACT, actin.) (B) Relative levels of VP mRNA in SCLC GLC-8 
cells. The striped bars represent the relative levels of VP mRNA after 
treatment with 0.5 mM 8,Br-CAMP and 0.5 mM IBMX which are ex- 
pressed as percentage of the levels measured after treatment with 0.5 
mM IBMX as vehicle alone, represented by the black bars. The values 
are the average ( f SEM) of six determinations done in three separate 
experiments. Statistics were performed with the Student’s t-test 
(P<O.oOl). ACT, actin; tRNA, total RNA; tDNA, total DNA. 
was tested in a heterologous expression system. The 
S ‘-flanking region from nucleotides - 174 to + 44 of 
the human VP gene [ 191 was cloned in front of the fire- 
fly luciferase gene in plasmid pl9LUC and transfected 
into mouse P 19 EC cells. This fusion gene had a consis- 
tent basal expression which was 2-3-fold higher than 
the promoterless plasmid pl9LUC. Treatment of 
transfected cells with 0.5 mM 8,Br-CAMP increased 
luciferase activity about 2-fold (Fig. 3). There was no 
effect of 8,Br-CAMP on luciferase activity when the 
promoterless vector PI9 was used (data not shown). 
IBMX alone had no effect on luciferase activity 
(Fig. 3). This result shows that the 5 ‘-flanking region 
91 
Volume 272, number 1,2 FEBS LETTERS October 1990 
Fig. 3. Effect of 8,Br-CAMP on luciferase activity in P19 EC cells 
after transfection of a VP gene luciferase construct. P19 EC cells were 
transientIy transfected with the 5 ‘-flanking region ( - 174 to + 44) to 
the human VP gene fused to the luciferase gene in plsmid pl9LUC. 
Transfected cells, not treated (A) and transfected cells treated with 0.5 
mM IBMX (B) or 0.5 mM IBMX and 0.5 mM 8,Br-CAMP (C). The 
values are the average (f SEM) of three separate determinations. 
Statistics were performed with the Student’s t-test (P<O.OOl). 
of the VP gene can confer responsiveness to cAMP and 
correlates with the increase in VP mRNA in the SCLC 
GLC-8 cell line after supplementation of the CAMP 
analogue. 
In these experiments we have directly investigated the 
putative involvement of cAMP in mediating effects on 
VP gene expression. Previously, the increase in CAMP 
levels and the G protein a-subunit mRNA in SON and 
PVN after osmotic stimulation [ 12,131 as well as the ef- 
fect of cAMP on the number of VP mRNA-containing 
neurons in primary hypothalamic cultures [14] have 
been taken as indications of an involvement of CAMP in 
VP gene regulation. This hypothesis is supported by the 
presence of putative AP2 binding elements in the 
5 ‘-flanking regions of mammalian VP genes [ 15-171. 
From the present results which were obtained in two 
different, independent expression systems, it is conclud- 
ed that the human VP gene is responsive to CAMP. 
Putative AP-2 binding elements are located in the VP 
promoter construct used in these experiments at posi- 
tions - 145 to - 136, - 110 to - 119, - 86 to - 95 and 
- 75 to - 84 (Fig. 4). Promoter deletion studies and 
direct tests of protein-DNA interactions can now be 
performed to identify the cis and trans-acting elements 
involved in the response to CAMP. Preliminary ex- 
periments indicate that the rat gene is similarly respon- 
sive to CAMP (Adan et al., unpublished results), which 
is not surprising in view of the high degree of homology 
between the 5’-flanking regions of the human and rat 
VP genes. The CAMP responsiveness of the VP gene 
may function in situations of hyperosmolality to in- 
crease VP mRNA levels and VP biosynthesis. In vivo it 
has been observed that the increase in VP mRNA is ac- 
companied by an increase in poly A tail size [28,29]. In 
our in vitro experiments with SCLC GLC-8 a change of 
poly A tail size in the VP transcript was not observed 
AP-2 consensus 5’ T C C C C A N G C G 3’ 
CCC 
human VP . 145 5’ T C C C C A G A T G 3’ - 136 
human VP . 110 5’ T C C C C A C C G G 3’ - 119 
humanVP 8.5 ST C C C C A G G A G 3’- 94 
humanVP - 74 ST C C C C A G T G G 3’- 83 
Fig. 4. Putative AP-2 binding elements in the 5 ‘-flanking region of 
the human VP gene. AP-2, activator protein 2. The numbering in- 
dicates the position of the elements upstream of the transcriptional 
start site. The consensus equences of AP-2 binding sites [17] and the 
homologous sequences in the human VP gene [ 191 are shown in bold. 
after 8,Br-CAMP treatment. This suggests that CAMP 
does not mediate the effect on mRNA size. Therefore, 
still other signal transduction pathways may be involv- 
ed in the full control of VP gene expression during 
osmotic stress. The SCLC GLC-8 cell line may also pro- 
vide a useful model system to define these factors. 
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